|
1) Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503-11
|
|
|
|
2) Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 1937-47
|
|
|
|
|
3) Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immuno-histochemistry using a tissue microarray. Blood. 2004; 103: 275-82
|
|
|
|
|
|
4) Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463: 88-92
|
|
|
|
|
|
5) Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008; 319: 1676-9
|
|
|
|
|
|
6) Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009; 459: 712-6
|
|
|
|
|
|
7) Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappa B in diffuse large B-cell lymphoma. Nature. 2009; 459: 717-21
|
|
|
|
|
|
8) Ngo VN, Young RM, Schmitz R, et al. Onco-genically active MYD88 mutations in human lymphoma. Nature. 2011; 470: 115-9
|
|
|
|
|
|
9) Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003; 102: 3871-9
|
|
|
|
|
|
10) Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004; 104: 543-9
|
|
|
|
|
|
11) Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008; 454: 226-31
|
|
|
|
|
|
12) Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006; 203: 311-7
|
|
|
|
|
|
13) Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008; 105: 13520-5
|
|
|
|
|
|
14) Schmidlin H, Diehl SA, Nagasawa M, et al. Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression. Blood. 2008; 112: 1804-12
|
|
|
|
|
|
15) Iqbal J, Greiner TC, Patel K, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007; 21: 2332-43
|
|
|
|
|
|
16) Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer. 2004; 109: 786-92
|
|
|
|
|
|
17) Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004; 165: 159-66
|
|
|
|
|
|
18) Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24: 961-8
|
|
|
|
|
|
19) Muris JJ, Cillessen SA, Vos W, et al. Immuno-histochemical profiling of caspase signaling pathways predicts clinical response to chemo-therapy in primary nodal diffuse large B-cell lymphomas. Blood. 2005; 105; 2916-23
|
|
|
|
|
|
20) Young KH, Weisenburger DD, Dave BJ, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood. 2007; 110: 4396-405
|
|
|
|
|
|
21) Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005; 207: 243-9
|
|
|
|
|
|
22) Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005; 102: 3627-32
|
|
|
|
|
|
23) He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005; 435: 828-33
|
|
|
|
|
|
24) Rai D, Karanti S, Jung I, et al. Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet. 2008; 181: 8-15
|
|
|
|
|
|
25) OʼDonnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435: 839-43
|
|
|
|
|
|
26) Xiao C, Srinivasan L, Calado DP, et al. Lympho-proliferative disease and autoimmunity in mice with increased miR-17-92 expression in lympho-cytes. Nature Immunol 2008; 9: 405-14
|
|
|
|
|
|
27) Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005; 105: 3671-8
|
|
|
|
|
|
28) Dijkman R, Tensen CP, Jordanova ES, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol. 2006; 24: 296-305
|
|
|
|
|
|
29) Camilleri-Broët S, Crinière E, Broët P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006; 107: 190-6
|
|
|
|
|
|
30) Booman M, Douwes J, Glas AM, et al. Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. J Pathol 2006; 210: 163-71
|
|
|
|
|
|
31) Sasaki N, Kuroda J, Nagoshi H, et al. Bcl-2 is a better therapeutic target than c-Myc, but attack-ing both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. Exp Hematol. 2011 May 11. [Epub ahead of print]
|
|
|
|
|
|
32) Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359: 2313-23
|
|
|
|
|
|
33) Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005; 105: 1851-61
|
|
|
|
|
|
34) Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011; 471: 189-95
|
|
|
|
|
|
35) Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011; 476: 298-303
|
|
|
|
|